Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.

ABSTRACT:

Background

The European LeukemiaNet (ELN) risk classification system for acute myeloid leukemia (AML) patients has been used worldwide. In 2022, the ELN risk classification system modified risk genes including CEBPA mutation status, myelodysplasia-related (MR) gene mutations and internal tandem duplications of FLT3 (FLT3-ITD).

Methods

We include newly diagnosed de novo AML patients at our center from January 2017 to December 2021, regardless of the further treatment received. Clinical data and date of survival were included. Survival analysis were performed using the Kaplan-Meier method, and the log-rank test was used to compare survival between different risk groups.

Results

We include 363 newly diagnosed de novo AML patients from 2017 to 2021 to assess the accuracy

SUBMITTER: Chen E 

PROVIDER: S-EPMC10757130 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature